FAMDF (Futura Medical) FCF Yield %: -274.01 (As of Jul. 15, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Futura Medical FCF Yield %?

Futura Medical FAMDF FCF Yield % is -274.01 as of Jul. 15, 2026. The stock has 5 warning signs investors should review. Among 1,409 Biotechnology companies, Futura Medical ranks worse than 96.45% on this metric.

FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

As of today, Futura Medical's Trailing 12-Month Free Cash Flow is $-7.57 Mil, and Market Cap is $2.76 Mil. Therefore, Futura Medical's FCF Yield % for today is -274.01%.

The historical rank and industry rank for Futura Medical's FCF Yield % or its related term are showing as below:

FAMDF' s FCF Yield % Range Over the Past 10 Years
Min: -465.56   Med: -10.02   Max: -0.7
Current: -274.01


During the past 13 years, the highest FCF Yield % of Futura Medical was -0.70%. The lowest was -465.56%. And the median was -10.02%.

FAMDF's FCF Yield % is ranked worse than
96.45% of 1409 companies
in the Biotechnology industry
Industry Median: -9.54 vs FAMDF: -274.01

Futura Medical's FCF Margin % for the quarter that ended in Dec. 2025 was -378.65%.


Futura Medical FCF Yield % Explanation

Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.


Futura Medical FCF Yield % Related Terms


Futura Medical FCF Yield % Historical Data

* Premium members only.

The historical data trend for Futura Medical's FCF Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Futura Medical FCF Yield % Chart

Futura Medical Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
FCF Yield %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -3.75 -4.44 -1.12 -1.46 -94.04

Futura Medical Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
FCF Yield % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.82 -7.24 5.56 -27.29 -88.30

FAMDF vs VRTX, REGN, ALNY: FCF Yield % Comparison

For the Biotechnology subindustry, Futura Medical's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Futura Medical FCF Yield % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Futura Medical's FCF Yield % distribution charts can be found below:

* The bar in red indicates where Futura Medical's FCF Yield % falls into.



Futura Medical FCF Yield % Calculation

FCF Yield % is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

Futura Medical's FCF Yield % for the fiscal year that ended in Dec. 2025 is calculated as

FCF Yield %=Free Cash Flow / Market Cap
=-7.517 / 7.99326
=-94.04%

Futura Medical's annualized FCF Yield % for the quarter that ended in Dec. 2025 is calculated as

FCF Yield %=Free Cash Flow * Annualized Factor / Market Cap
=-3.529 * 2 / 7.99326
=-88.30%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about FCF Yield % →
What does a FCF Yield % of -274.01 mean?
Futura Medical (FAMDF) has a FCF Yield % of -274.01 as of Jul. 15, 2026. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Futura Medical and its competitors. According to the industry distribution chart, Futura Medical ranks #1359 out of 1409 companies in the Biotechnology industry, placing it in the top 96.5%.
Is Futura Medical's FCF Yield % too high?
Futura Medical's current FCF Yield % is -274.01. Based on the distribution chart, Futura Medical ranks #1359 out of 1409 companies in the Biotechnology industry, which is in the bottom quartile relative to peers.
How does Futura Medical's FCF Yield % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Futura Medical ranks #1359 out of 1409 companies for FCF Yield %. This places Futura Medical in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Yield % for a Biotechnology company?
A good FCF Yield % depends on the Biotechnology industry context. However, FCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Yield % mean?
A high FCF Yield % can signal that a stock is expensive relative to its fundamentals. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Futura Medical and its competitors. Futura Medical's current FCF Yield % is -274.01. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Futura Medical stock overvalued right now?
Based on GuruFocus' analysis, Futura Medical (FAMDF) is currently considered Possible Value Trap. The stock's GF Value™ is $0.08, compared to a current price of $0.01 — trading 87.5% below its estimated fair value. The current FCF Yield % is -274.01. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Yield % calculated?
FCF Yield % is calculated from a company's financial statements. For Futura Medical (FAMDF), the current FCF Yield % is -274.01 as of Jul. 15, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Futura Medical Business Description

Other Exchanges FUMl:UKFUM:UKGYX:Germany
Address 40 Occam Road, Surrey Technology Centre, Guildford, Surrey, GBR, GU2 7YG
Futura Medical PLC is engaged in the development and commercialization of sexual health products. Its product Eroxon is a treatment for erectile dysfunction. Geographically, the company derives the majority of its revenue from the United Kingdom and the European Union.